Lada Mitchell

6.2k total citations · 2 hit papers
35 papers, 4.5k citations indexed

About

Lada Mitchell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lada Mitchell has authored 35 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Lada Mitchell's work include HER2/EGFR in Cancer Research (9 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Lada Mitchell is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Lada Mitchell collaborates with scholars based in Switzerland, Spain and United Kingdom. Lada Mitchell's co-authors include Tsushung A. Hua, Michael A. Weber, John H. Laragh, Hans R. Brunner, Gordon T. McInnes, Alberto Zanchetti, Steffan Ekman, Francis Plat, Beverly A. Smith and Stevo Julius and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Lada Mitchell

33 papers receiving 4.2k citations

Hit Papers

Outcomes in hypertensive patients at high cardiovascular ... 2003 2026 2010 2018 2004 2003 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    2004 1.8k citations Stevo Julius, Sverre E. Kjeldsen et al. The Lancet profile →
  2. Applied Multivariate Statistics for the Social Sciences
    2003 854 citations Lada Mitchell Journal of the Royal Statistical Society Series D (The Statistician) profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lada Mitchell Switzerland 14 2.1k 1.1k 799 618 602 35 4.5k
Hyun‐Young Park South Korea 45 1.6k 0.8× 1.0k 0.9× 363 0.5× 396 0.6× 1.2k 2.0× 300 6.9k
Mei Zhang China 41 1.1k 0.5× 1.4k 1.3× 416 0.5× 330 0.5× 1.4k 2.3× 207 7.7k
Anna Peeters Australia 51 1.2k 0.6× 1.4k 1.3× 326 0.4× 282 0.5× 441 0.7× 318 10.9k
Xian Li China 36 1.1k 0.5× 407 0.4× 313 0.4× 333 0.5× 1.1k 1.8× 235 5.3k
Cristiana Vitale Italy 43 2.2k 1.0× 1.7k 1.6× 248 0.3× 292 0.5× 769 1.3× 159 5.9k
Samuli Ripatti Finland 49 959 0.5× 677 0.6× 286 0.4× 358 0.6× 2.4k 4.0× 168 8.5k
Catherine A. McCarty United States 64 641 0.3× 471 0.4× 738 0.9× 257 0.4× 2.2k 3.7× 307 13.5k
Karen L. Edwards United States 43 722 0.3× 1.6k 1.4× 277 0.3× 400 0.6× 878 1.5× 147 6.1k
José Leal United Kingdom 30 1.2k 0.6× 907 0.8× 479 0.6× 376 0.6× 488 0.8× 115 6.0k

Countries citing papers authored by Lada Mitchell

Since Specialization
Citations

This map shows the geographic impact of Lada Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lada Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lada Mitchell more than expected).

Fields of papers citing papers by Lada Mitchell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lada Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lada Mitchell. The network helps show where Lada Mitchell may publish in the future.

Co-authorship network of co-authors of Lada Mitchell

This figure shows the co-authorship network connecting the top 25 collaborators of Lada Mitchell. A scholar is included among the top collaborators of Lada Mitchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lada Mitchell. Lada Mitchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiely, David G., Richard N. Channick, Dayana Flores, et al.. (2024). Comparison of cardiac magnetic resonance imaging, functional and haemodynamic variables in pulmonary arterial hypertension: insights from REPAIR. ERJ Open Research. 10(1). 547–2023. 1 indexed citations
2.
Chin, Kelly, Richard N. Channick, Nick H. Kim, et al.. (2024). Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiology and Therapy. 13(4). 775–796. 1 indexed citations
3.
Channick, Richard N., Kelly Chin, Vallerie V. McLaughlin, et al.. (2024). Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset. Cardiology and Therapy. 13(2). 315–339. 2 indexed citations
4.
Coghlan, Gerry, Seán Gaine, Richard N. Channick, et al.. (2022). Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension. ERJ Open Research. 9(1). 456–2022. 11 indexed citations
5.
Mueller, Volkmar, Magdolna Dank, Sabine de Ducla, Lada Mitchell, & Andreas Schneeweiß. (2016). Real-world effectiveness and safety of first-line bevacizumab (BEV) + paclitaxel (PAC) in >2000 patients (pts) with HER2-negative metastatic breast cancer (mBC). Annals of Oncology. 27. vi73–vi73. 1 indexed citations
6.
7.
Kurzeder, Christian, Isabel Bover, Frederik Marmé, et al.. (2015). Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. Journal of Clinical Oncology. 33(15_suppl). 5504–5504. 5 indexed citations
8.
González-Martı́n, Antonio, Amit M. Oza, Andrew Embleton-Thirsk, et al.. (2015). Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV) for ovarian cancer (OC).. Journal of Clinical Oncology. 33(15_suppl). 5548–5548. 3 indexed citations
9.
Larkin, James, Michele Del Vecchio, Paolo A. Ascierto, et al.. (2014). Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet Oncology. 15(4). 436–444. 193 indexed citations
10.
Dummer, Reinhard, Simone M. Goldinger, Christian P. Turtschi, et al.. (2013). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer. 50(3). 611–621. 230 indexed citations
11.
Grob, Jean‐Jacques, Rainer Kunstfeld, Brigitte Dréno, et al.. (2013). Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.. Journal of Clinical Oncology. 31(15_suppl). 9036–9036. 11 indexed citations
12.
Martín, Miguel, А. Н. Махсон, Joseph Gligorov, et al.. (2012). Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. The Oncologist. 17(4). 469–475. 40 indexed citations
13.
Perez, Edith A., José Manuel López-Vega, Lucia Del Mastro, et al.. (2012). A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).. Journal of Clinical Oncology. 30(15_suppl). TPS653–TPS653. 11 indexed citations
14.
Rimawi, Mothaffar F., Christopher Poole, Jean-­Marc Ferrero, et al.. (2012). Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).. Journal of Clinical Oncology. 30(15_suppl). TPS654–TPS654. 8 indexed citations
15.
Larkin, James, Paola Queirolo, Ana Arance, et al.. (2012). An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.. Journal of Clinical Oncology. 30(15_suppl). 8517–8517. 13 indexed citations
16.
Dummer, Reinhard, Simone M. Goldinger, Christian P. Turtschi, et al.. (2012). Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM). Annals of Oncology. 23. ix366–ix366. 12 indexed citations
17.
Weber, Michael A., Stevo Julius, Sverre E. Kjeldsen, et al.. (2004). Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. The Lancet. 363(9426). 2049–2051. 428 indexed citations
18.
Julius, Stevo, Sverre E. Kjeldsen, Michael A. Weber, et al.. (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 363(9426). 2022–2031. 1845 indexed citations breakdown →
19.
Greenough, Anne, et al.. (2003). Lercanidipine vs lacidipine in isolated systolic hypertension. Journal of Human Hypertension. 17(11). 799–806. 11 indexed citations
20.
Mitchell, Lada. (2003). Generalized, Linear, and Mixed Models. Journal of the Royal Statistical Society Series D (The Statistician). 52(2). 242–243. 216 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyun‐Young Park Breakdown of academic impact, for papers by Mei Zhang Breakdown of academic impact, for papers by Anna Peeters Breakdown of academic impact, for papers by Xian Li Breakdown of academic impact, for papers by Cristiana Vitale Breakdown of academic impact, for papers by Samuli Ripatti Breakdown of academic impact, for papers by Catherine A. McCarty Breakdown of academic impact, for papers by Karen L. Edwards Breakdown of academic impact, for papers by José Leal
Rankless by CCL
2026